亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Use of Ritonavir and Metformin for treatment of Multiple Myeloma

技術優勢
Provides an effective method to target cancer metabolism Repurposes current therapeutics Combination therapy yields potent lethality across a variety of cancers in cell-based studies
詳細技術說明
Novel approach to treating multiple myeloma and other cancers using existing therapeutics. #therapeutics #cancer
*Abstract

Northwestern researchers have identified a novel approach to treating cancers that demonstrate high glucose metabolism, such as multiple myeloma (MM), using existing therapeutics. Elevated glucose metabolism is a key diagnostic and prognostic indicator in MM. GLUT4 plays a major role in this process and inhibition of this protein results in inhibition of cell growth and/or apoptosis. MM cells resistant to GLUT4 inhibition switch to utilize mitochondrial metabolism coupled to oxidative phosphorylation to maintain viability. The novel approach centers on repurposing HIV protease inhibitors (ritonavir/indinavir) that inhibit GLUT4 and using them in combination with metformin (GLUCOPHAGE) that can be used to target mitochondrial oxidative phosphorylation. 

*Inventors
Malathy Shanmugam* Steven T. Rosen
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備